Charles River Laboratories International Inc. (CRL)

NYSE: CRL · USD

$374

+15.29 (+4.3%)· Recorded snapshot

영어 원본으로 대체KO

번역하는 동안 영어 원본을 표시 중

이 리포트는 아직 번역되지 않았습니다. 번역 대기열이 따라잡으면 몇 분 후에 새로고침하세요.

StockMarketAgent Research · Analyzed 2026-09-20

Our latest published analysis: CRL rated Sell

Charles River Laboratories International Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$131 / share

Potential value

$158 / share

Upside to FV

-52.8%

from $374

Moat

6.5/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$13.4B
Revenue (ttm)	4B
Net income (ttm)	-238.5M
EPS (ttm)	-$4.88
Shares out	47.7M
P/E (forward)	22.5x
Volume	1,085,812
Beta	1.40

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 4B
Net income (ttm): -238.5M
EPS (ttm): -$4.88
P/E (forward): 22.5x
Market cap: $13.4B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-25	2022-12-31	2023-12-30	2024-12-28	2025-12-27	Trend
Revenue	$3.54B	$3.98B	$4.13B	$4.05B	$4.02B	+3.2%
Gross profit	$1.33B	$1.46B	$1.50B	$1.33B	$1.23B	-2.1%
Operating income	$589.9M	$651.0M	$617.3M	$227.3M	$25.2M	-54.6%
Net income	$391.0M	$486.2M	$474.6M	$22.2M	$-144.3M	—
EPS (diluted)	$7.60	$9.48	$9.22	$0.20	$-2.91	—
EBITDA	$820.2M	$986.1M	$1.03B	$581.1M	$410.8M	-15.9%
R&D	—	—	—	—	—	—
SG&A	$619.9M	$665.1M	$747.9M	$751.0M	$743.1M	+4.6%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	5T	39.4x	10.8x	101.6%	+6.1%	+28.5%	매도
ABNB	Airbnb, Inc.	97.8B	37.5x	7.4x	16.8%	+24.4%	+28.5%	매도
ADBE	Adobe Inc.	97.1B	13.9x	3.7x	57.2%	+11.5%	-30.7%	적극 매수
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	매도
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	비중 축소
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	비중 축소

Base and Bull scenarios

Base45%

Price target

$131.31

-52.8% from spot

Under the base scenario, which carries a probability of 45.0%, biopharmaceutical preclinical study demand stabilizes following near-term budget austerity, and operational restructuring in Manufacturing Support eliminates segment operating losses. Normalized consolidated operating margins expand steadily toward peer benchmarks, driving the equity valuation to $367.67, representing an expected return of 32.2% relative to $278.06. This path is disconfirmed if early-stage biotechnology study cancellations accelerate or if fixed facility costs prevent margin expansion over the next several fiscal quarters.

Discovery and Safety Assessment revenue returns to low-single-digit growth following near-term biopharma budget stabilization
Operating margin normalizes gradually toward peer levels as Manufacturing Support losses are eliminated
Terminal valuation multiple anchors to established healthcare testing peer levels
Free cash flow conversion remains healthy, enabling steady balance sheet debt reduction

Bull25%

Price target

$158.12

-43.1% from spot

In the bull scenario, assigned a probability of 25.0%, a decisive recovery in global biopharma venture funding spurs candidate progression into IND-enabling toxicology studies. Discovery and Safety Assessment study volume re-accelerates sharply, allowing substantial fixed-cost operating leverage to drive consolidated margins above peer benchmarks. Combined with a successful turnaround in Manufacturing Support and rapid debt repayment, equity value reaches Potential value of $459.24, delivering a return of 65.2% from $278.06. Investors would confirm this trajectory through sequential quarterly revenue growth re-acceleration and expanding backlog over the next year.

Robust resurgence in global biotechnology venture capital funding and public capital market access
Rapid re-acceleration in IND-enabling safety assessment study starts across North America and Europe
Manufacturing Support completes operational turnaround and achieves positive operating profit contribution
Valuation multiple expands toward high-growth life sciences tools and testing peer levels

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($131.31). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	2.0%	2.5%	3.0%	3.5%	4.0%
7.9%	$142	$142	$142	$142	$142
8.9%	$137	$137	$137	$137	$137
9.9%	$131	$131	$131	$131	$131
10.9%	$126	$126	$126	$126	$126
11.9%	$122	$122	$122	$122	$122

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E22.5

P25 n/aP50 n/aP75 n/a

Trailing P/E0

P25 n/aP50 n/aP75 n/a

ROE-7.5

P25 n/aP50 n/aP75 n/a

ROIC8.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All CRL indicators

Market & fundamental data

Available fields

252

Groups with data

Currency

USD

Showing 252 of 252 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001100682
Company name	Charles River Laboratories International, Inc.
Country	United States
Country code	US
CUSIP number	159864107
Earnings date	2026-11-04
Earnings time	bmo
Employees	19,700
Employees change	-400
Employees growth	-1.99%
Enterprise value	$20.7B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-27
First seen	2026-05-09
Fiscal year end	December
Founded	1947
In index	SP500
Industry	Diagnostics & Research
IPO date	2000-06-23
Is primary listing	Yes
Is SPAC	No
ISIN number	US1598641074
Last 10-K release date	2026-02-18
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$17.9B
Market cap category	Large-Cap
Next earnings date	2026-11-04
Options	Yes
Price	$374.13
Price currency	USD
Sector	Healthcare
SIC code	8731
Stock price date	2026-10-28
Symbol	CRL
U.S. state	Massachusetts
Website	https://www.criver.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	37.79x
Average P/E ratio (10Y)	57.65x
Average P/E ratio (5Y)	93.23x
Earnings yield	-1.3%
EV/EBIT	41.45x
EV/EBITDA	24.2x
EV/FCF	55.45x
EV/Sales	5.14x
FCF / EV yield	1.8%
FCF yield	2.09%
Forward EV/Sales	5.26x
Forward P/E	30.4x
Forward P/S	4.53x
Industry forward P/E	30.87x
Industry P/E	50.24x
P/(FCF - SBC) ratio	61.58x
P/(OCF - SBC) ratio	35.48x
P/B ratio	6.03x
P/FCF ratio	47.78x
P/OCF ratio	30.42x
P/S ratio	4.43x
PEG ratio	2.49x
Price/EBITDA ratio	20.85x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	12.4%
EBITDA margin	21.23%
FCF margin	9.27%
Gross margin	34.59%
Operating margin	12.4%
Pretax margin	-4.59%
Profit margin	-5.96%
Profit per employee	$-12,104
Revenue per employee	$202,994
ROA	4.11%
ROA (5Y)	5.15%
ROCE	7.75%
ROE	-7.52%
ROE (5Y)	9.05%
ROIC	8.56%
ROIC (5Y)	8.01%
SBC / revenue	2.08%
Tax / revenue	1.32%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
FCF growth	-35.94%
FCF growth (Q)	-12.22%
FCF growth 3Y	8.6%
FCF growth 5Y	-5.2%
Gross profit growth	-1.99%
Gross profit growth (Q)	-1.18%
Gross profit growth 3Y	-3.86%
Gross profit growth 5Y	2.19%
Net income growth years	0
OCF growth	-26.07%
OCF growth (Q)	-12.16%
OCF growth (QoQ)	337.53%
OCF growth 10Y	6.34%
OCF growth 3Y	-2.34%
OCF growth 5Y	-2.84%
Operating income growth	-7.31%
Operating income growth (Q)	-11.79%
Operating income growth 3Y	-9.11%
Operating income growth 5Y	-2.28%
Revenue growth	-0.74%
Revenue growth (Q)	-2.72%
Revenue growth (QoQ)	0.83%
Revenue growth 10Y	10.36%
Revenue growth 3Y	-1.45%
Revenue growth 5Y	4.09%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-211.5M
Depreciation and amortization	$353.3M
EBIT	$495.8M
EBITDA	$849.1M
EPS	$-4.88
FCF per share	$7.76
Financing cash flow	$-21.4M
Free cash flow	$370.6M
Free cash flow minus SBC	$287.5M
Gross profit	$1.4B
Income taxes	$52.6M
Investing cash flow	$-506.3M
Net borrowing	$321.9M
Net cash flow	$55.8M
Net income	$-238.5M
Operating cash flow minus SBC	$499.1M
Operating income	$495.8M
Revenue	$4B
Stock-based compensation	$83.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	2.18
Book value per share	$59.50
Debt / EBITDA	3.15
Debt / equity	1.05
Debt / FCF	8.19
Goodwill	$3.1B
Interest coverage	4.67
Long-term assets	$6B
Long-term liabilities	$3.5B
Net cash (debt)	$-2.8B
Net cash / market cap	-16.05%
Net debt / EBITDA	3.35
Net debt / equity	0.98
Net debt / FCF	7.67
Piotroski F-Score	4
Property, plant and equipment	$1.8B
Shareholders' equity	$2.9B
Tangible book value	$-490.4M
Tangible book value per share	$-10.27
Total assets	$7.5B
Total cash	$192M
Total debt	$3B
Total liabilities	$4.6B
WACC	10.63%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.53
Current assets	$1.5B
Current liabilities	$1.1B
Current ratio	1.35
Inventory turnover	8.36
Net working capital	$209M
Quick ratio	0.8
Working capital	$394.4M
Working capital turnover	10.2

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	3.44%
Dividend yield	0%
Shareholder yield	3.44%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	389.19%
10Y return CAGR	17.21%
10Y total return	389.19%
150-day SMA	$232.68
15Y price change	1,039.95%
15Y return CAGR	17.61%
15Y total return	1,039.95%
1D price change	4.26%
1M price change	27.76%
1M total return	27.76%
1W price change	8.48%
1W total return	8.48%
1Y price change	91.59%
1Y return CAGR	91.67%
1Y total return	91.59%
20-day SMA	$316.89
200-day SMA	$220.28
20Y price change	761.06%
20Y return CAGR	11.37%
20Y total return	761.06%
3M price change	66.8%
3M total return	66.8%
3Y price change	116.77%
3Y return CAGR	29.41%
3Y total return	116.77%
50-day SMA	$298.83
50-day SMA vs 200-day SMA	50over200
52-week high	$377.72
52-week high date	2026-10-28
52-week low	$146.20
52-week low date	2026-05-19
5Y price change	-13.01%
5Y return CAGR	-2.75%
5Y total return	-13.01%
6M price change	118.5%
6M total return	118.5%
All-time high	$460.21
All-time high date	2021-09-24
All-time low	$17.19
All-time low date	2000-12-11
Average true range (ATR)	$13.49
Average volume	1.1M
Beta (1Y)	1.45
Beta (2Y)	0.78
Beta (5Y)	1.4
Change from 52-week high	-1.08%
Change from 52-week low	155.91%
Change from all-time high	-18.7%
Change from all-time low	2,076.69%
Change from open	3.21%
Day's gap	1.01%
Dollar volume	$406.2M
High price	$377.72
Low price	$362.48
Monthly RSI	75.81
Open price	$362.48
Position in 52-week range	76.44%
Premarket change	-0.51%
Premarket close	$358.84
Premarket price	$357.00
Previous close	$358.84
Price vs 150-day SMA	60.79%
Price vs 20-day SMA	18.06%
Price vs 200-day SMA	69.84%
Price vs 50-day SMA	25.2%
Relative volume	0.98
RSI	80.27
Sharpe ratio	1.56
Sharpe ratio (3Y)	0.67
Sharpe ratio (5Y)	0.08
Sortino ratio	2.64
Sortino ratio (3Y)	1.11
Sortino ratio (5Y)	0.24
Volume	1.1M
Weekly RSI	82.14
YTD price change	87.55%
YTD total return	87.55%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	47.2M
Float percentage	98.86%
Shares change (QoQ)	-1.9%
Shares change (YoY)	-3.44%
Shares held by insiders	0.99%
Shares held by institutions	121.32%
Shares outstanding	47.7M
Short % of float	6.1%
Short % of shares	6.03%
Short ratio	3 days

Deeper analysis on CRL

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this CRL report

What is the latest published CRL stock rating?

Charles River Laboratories International Inc. is shown with Sell in the latest published report, analyzed 2026-09-20. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full CRL analysis?

The full latest published report, analyzed 2026-09-20, lives at /stocks/CRL/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for CRL?

The latest published report analyzed 2026-09-20 gives CRL a fair value of USD 131 and a potential value of USD 158. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the CRL page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-09-20). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

SellCRL · Fair value $131-52.8%

Read full analysis →

Charles River Laboratories International Inc. (CRL)

Our latest published analysis: CRL rated Sell

Price

Financial snapshot

Fair-value bridge

Latest news · CRL

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All CRL indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on CRL

Frequently asked questions

등급 이력

Category	Score	Reading
Valuation	1.5
Management	6.5
Balance Sheet	5.0
Profitability	1.5
Revenue Growth	2.5
Risk Assessment	6.0
Competitive Moat	6.5
Earnings Quality	3.0
Capital Efficiency	3.5